|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
These genes include GRM7, previously associated to major depression disorder and bipolar disorder, SLC6A13, in anxiety disorders, and S100B, SSTR5 and COMT in schizophrenia.
|
20398908 |
2010 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
Our results may indicate that the SSTR5 gene is involved in the etiology of BPAD or may exist in linkage disequilibrium with a susceptibility gene close to SSTR5.
|
12192619 |
2002 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Our results may indicate that the SSTR5 gene is involved in the etiology of BPAD or may exist in linkage disequilibrium with a susceptibility gene close to SSTR5.
|
12192619 |
2002 |
|
Unipolar Depression
|
0.300 |
Biomarker
|
disease |
PSYGENET |
These genes include GRM7, previously associated to major depression disorder and bipolar disorder, SLC6A13, in anxiety disorders, and S100B, SSTR5 and COMT in schizophrenia.
|
20398908 |
2010 |
|
Major Depressive Disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
These genes include GRM7, previously associated to major depression disorder and bipolar disorder, SLC6A13, in anxiety disorders, and S100B, SSTR5 and COMT in schizophrenia.
|
20398908 |
2010 |
|
Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
At 4 weeks after SE, SRIF1-family (SSTR 2A, SSTR2B, and SSTR5) immunoreactivity was increased only in neuropil.
|
18951627 |
2009 |
|
Petit mal status
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Grand Mal Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Complex Partial Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Status Epilepticus, Subclinical
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Non-Convulsive Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Simple Partial Status Epilepticus
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Pituitary and hypothalamic somatostatin receptor subtype messenger ribonucleic acid expression in the food-deprived and diabetic rat.
|
7956902 |
1994 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The intensity of SSTR5 expression and the granulation pattern of adenomas were of limited value for the prediction of Pasireotide-LAR effectiveness.
|
31518993 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SSTR1 to SSTR5 expression in PC tumors.
|
30657933 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found somatostatin receptor type 5 (SST5) expressed in 17 different ACTH-secreting tumors and SST2 detectable in 15 out of the 17 tissues.
|
30611770 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IHC evaluation of tumor samples from two patients (a responder and a non-responder) revealed positive immunostaining for PRL and SSTR5 but not for other pituitary hormones or for SSTR2.
|
29948930 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies to somatostatin receptors 2A (SSTR2A, UMB-1) and 5 (SSTR5, UMB-4) were reported to be highly reliable for immunohistochemical detection of these receptors in neuroendocrine neoplasms.
|
29180250 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Neither sinonasal carcinomas nor sinonasal small round blue cell neoplasms expressed SSTR2A or SSTR5.
|
29807052 |
2018 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RESULTS IHC of SSTR subtypes in the different cohorts showed SSTR2 staining intensity scores higher than SSTR5 in TSHoma, acromegaly and prolactinoma, whereas the expression of SSTR5 was stronger than SSTR2 in corticotropinoma and NFPA.
|
28434012 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Similarly, SSTR5 was increased in pancreatic and well-differentiated tumors.
|
28454229 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, the protein expression of SSTR2, but not of SSTR5, is a valuable indicator in predicting biochemical and tumor size response to short-term SSA treatment in acromegalic patients.
|
28396686 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CXCR4 and SSTR1 were present in 60% and 67% of the CCC samples, respectively, followed by SSTR2 and SSTR5, which were detected in 30% and 11% of the tumors, respectively.
|
29282035 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
All the eight tumor specimens expressed high SSTR2 protein levels; 5/8 expressed high SSTR5, but 3/8 that expressed low SSTR5 presented a significantly higher TSH suppression rate (P = 0.036).
|
28397723 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
One well-differentiated and two poorly differentiated neuroendocrine neoplasms expressed somatostatin receptor 5.
|
28059098 |
2017 |